Evaluation of Long-Term Safety and Efficacy of Vanzacaftor/Tezacaftor/Deutivacaftor in Cystic Fibrosis Participants 1 Year of Age and Older

Enrolling by invitation · Phase 3

Conditions studied: Cystic Fibrosis

In brief

The purpose of this study is to evaluate the long-term safety, tolerability, and efficacy of vanzacaftor/tezacaftor/deutivacaftor (VNZ/TEZ/D-IVA) in participants with cystic fibrosis (CF).

Key facts

Study ID
NCT05844449
Run by
Vertex Pharmaceuticals Incorporated
People needed
174
Starts
2023-08-11
Expected to finish
2029-07-30
Last updated by the study team
2026-04-29

Who can join

Age: 1 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.